Alias |
Amyloid beta A4 protein, ABPP, APPI, Short name=APP, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, Short name=CVAP, PreA4, Protease nexin-II, Short name=PN-II, N-APP, Soluble APP-alpha, Short name=S-APP-alpha, Soluble APP-beta, Short name=S-APP-beta, Beta-amyloid protein 42, Beta-APP42, Beta-amyloid protein 40, Beta-APP40, P3(42), P3(40), Gamma-secretase C-terminal fragment 59, Amyloid intracellular domain 59, Short name=AICD-59, Short name=AID(59), Gamma-CTF(59), Gamma-secretase C-terminal fragment 57, Amyloid intracellular domain 57, Short name=AICD-57, Short name=AID(57), Gamma-CTF(57), Gamma-secretase C-terminal fragment 50, Amyloid intracellular domain 50, AICD-50, AID(50), Gamma-CTF(50), APP, A4, AD, Amyloid-β, Amyloid β, Amyloidβ, β Amyloid, βAmyloid, Aβ |
Background |
Proteolytic cleavage of the Amyloid protein precursor (APP) gives rise to the β-Amyloid and Amyloid A4 proteins, which are present in human platelets. Amyloid deposition is associated with type II diabetes, Down syndrome and a variety of neurological disorders, including Alzheimer’s disease. The Amyloid precursor protein (APP) undergoes alternative splicing, resulting in several isoforms. Proteolytic cleavage of APP leads to the formation of the Amyloid β/A4 Amyloid protein. This protein is involved in the formation of neurofibrillary tangles and plaques that characterize the senile plaques of Alzheimer’s patients. APLP1 (Amyloid precursor-like protein 1) and APLP2 are structurally similar to APP. |